Remicade Biosimilars Market Growth Outlook and Opportunity Analysis to 2026

Remicade Biosimilars Market Size, Share,
Trend, Outlook, Future Growth Analysis
And Synthesis 2018 - 2026
Biosimilar refers to biotherapeutic product that is similar in terms of quality, efficacy, and safety to an
existing licensed reference therapeutic drug. Biological products are the fastest growing class of
therapeutic products, as they offer additional treatment options and help in lowering healthcare costs.
Biosimilars are almost identical copies of the originally approved drugs and can be manufactured only
when the patent for the original innovator drug expires. These products are highly sensitive to smallest
changes in manufacturing procedure, as these drugs possess high molecular complexity. Remicade
(Infliximab) refers to a chimeric monoclonal antibody biologic licensed by U.S. FDA in 1998, as an
innovative product indicated for the treatment of Crohn’s disease in adults and children. The monoclonal
antibody drug was first developed in partnership by Janssen Biotech, Inc. and Merck & Co. The
Remicade was later approved for its use in the treatment of ulcerative colitis, plague psoriasis,
rheumatic arthritis, and spinal psoriatic arthritis in combination with methotrexate. Later, various
pharmaceutical manufacturers developed biosimilars to infliximab, which lowered market share of
Remicade due to cost-effective prices.
Free Request Sample of Report: https://www.coherentmarketinsights.com/insight/request-sample/1769
Market Dynamics
Increasing incidence of autoimmune diseases such as plaque psoriasis and rheumatoid arthritis are
expected to drive growth of the Remicade biosimilar market size. According to the American
Autoimmune Related Disease Association, around 50 million American suffered from autoimmune
diseases in the U.S. in 2017. Moreover, faster reaction rates of these biosimilars due to their availability
in the form of intravenous mode of administration is further expected to increase the adoption of
Remicade biosimilar over the forecast period. Furthermore, patent expiry of the branded versions is
expected to increase the number of biosimilars for its branded counterparts thereby increasing the
demand for Remicade biosimilar. However, stringent regulatory guidelines for development of these
biosimilars as well as side effects of these drugs leading to risk of hospitalization are expected to
restrain growth of the global Remicade biosimilar market.
Regional Insights
On the basis of region, the global Remicade biosimilar market is segmented into North America, Latin
America, Europe, Asia Pacific, Middle East, and Africa. Europe holds a dominant position in the global
Remicade biosimilar market and is expected to retain its dominance over the forecast period, owing to
the presence of top market players in the region, rapid entry of biosimilars in the European market as
well as high adoption rate due low price of the biosimilars. For instance, in 2018, Sandoz, a Novartis
division received European Commission (EC) approval for Zessly (infliximab) a remicade biosimilar for
use in Europe. The successive research and speedy approvals by the U.S. regulatory authorities for
market entry of biosimilars in North America is expected to drive growth of the market over the forecast
period. For instance, in December 2017, Pfizer, Inc. received the U.S. FDA approval for second
biosimilar, Ifixi to Janssen’s blockbuster drug Remicade to treat rheumatoid arthritis.
Report includes chapters which deeply display the following deliverable about industry :
• Remicade Biosimilars Market Research Objective and Assumption
• Remicade Biosimilars Market Purview - Report Description, Executive Summary, and Coherent
Opportunity Map (COM)
• Remicade Biosimilars Market Dynamics, Regulations, and Trends Analysis - Market Dynamics,
Regulatory Scenario, Industry Trend, Merger and Acquisitions, New system Launch/Approvals,
Value Chain Analysis, Porter’s Analysis, and PEST Analysis
• Global Remicade Biosimilars Market, By Regions
• Remicade Biosimilars Market Competition by Manufacturers including Production, Share,
Revenue, Average Price, Manufacturing Base Distribution, Sales Area and Product Type.
• Remicade Biosimilars Market Manufacturers Profiles/Analysis including Company Basic
Information, Manufacturing Base and Its Competitors.
• Remicade Biosimilars Market Manufacturing Cost Analysis including Key Raw Materials and
Key Suppliers of Raw Materials.
• Industrial Chain, Sourcing Strategy and Downstream Buyers including Upstream Raw Materials
Sourcing and Downstream Buyers
• Marketing Strategy Analysis, Distributors/Traders including Marketing Channel, Market
Positioning and Distributors/Traders List.
• Market Effect Factors Analysis including Technology Progress/Risk, Consumer Needs/Customer
Preference Change and Economic/Political Environmental Change.
• Remicade Biosimilars Market Forecast including Production, Consumption, Import and Export
Forecast by Type, Applications and Region.
• Research Findings and Conclusion
Competitive Landscape
Key players operating in the global remicade biosimilar market include Janssen Biotech, Inc., Merck and
Company, Inc., Alvogen, Pfizer, Inc., Celltrion, Nippon Kayaku, Napp Pharmaceuticals, and others.
Market players are focused on introducing maximum number of biosimilar for multiple indications to
retain their position in the global market. For instance, in July 2017, Merck & Company, Inc. in
collaboration with Samsung Bioepis introduced Renflexis (infliximab-abda), a biosimilar to Remicade for
the treatment of moderate to severe Crohn’s disease, active ulcerative colitis, rheumatoid arthritis, and
other few disease indications.
The increasing prevalence of rare cancer in patients owing to oncological diseases segment to dominate
in the orphan drugs market
The global orphan drugs market is segmented on the basis of disease, by product type and by region
On the basis of disease type,
•
Hematologic and Immunologic diseases
•
Infectious diseases
•
Metabolic diseases
•
Neurologic diseases
•
Oncologic diseases
•
Other orphan diseases
On the basis of product type,
•
Biological orphan drugs
•
Non-biological orphan drugs
Browse In-Depth Analysis Research Report @ https://www.coherentmarketinsights.com/ongoinginsight/remicade-biosimilars-market-1769
About Coherent Market Insights
Coherent Market Insights is a prominent market research and consulting firm offering actionready syndicated research reports, custom market analysis, consulting services, and competitive
analysis through various recommendations related to emerging market trends, technologies, and
potential absolute dollar opportunity.
Contact Us
Mr. Shah
Coherent Market Insights
1001 4th Ave, #3200
Seattle, WA 98154
Tel: +1-206-701-6702
Email: sales@coherentmarketinsights.com

Remicade Biosimilars Market – Size, Share, Outlook, and Opportunity Analysis 2018 - 2026